Table 3. Reconstructed haplotypes and the association with risk of developing late skin toxicity (telangiectasia) with score ⩾2 after radiotherapy.
Gene | Haplotype | Frequency | ORa | 95% CI |
---|---|---|---|---|
All patients | ||||
TP53 | GA1 | 0.71 | 1 | |
GA2 | 0.03 | 1.02 | 0.29–3.63 | |
CA1 | 0.16 | 1.20 | 0.79–1.82 | |
CA2b | 0.11 | 1.97 | 1.11–3.52 | |
Patients without acute toxicity during radiotherapy c | ||||
TP53 | GA1 | 0.71 | 1 | |
GA2 | 0.02 | 0.68 | 0.13–3.60 | |
CA1 | 0.16 | 1.15 | 0.71–1.85 | |
CA2 | 0.12 | 2.78 | 1.44–5.37 | |
Patients with acute toxicity during radiotherapy | ||||
TP53 | GA1 | 0.71 | 1 | |
GA2 | 0.04 | 1.10 | 0.09–13.41 | |
CA1 | 0.17 | 1.47 | 0.52–4.17 | |
CA2 | 0.09 | 0.52 | 0.11–2.53 | |
All patients | ||||
XRCC1 | CCGG | 0.41 | 1 | |
TCGG | 0.12 | 1.15 | 0.66–2.00 | |
TCGA | 0.36 | 0.78 | 0.53–1.15 | |
TTGG | 0.05 | 0.51 | 0.21–1.24 | |
Rared | 0.07 | 0.56 | 0.26–1.20 | |
XPD | GA | 0.56 | 1 | |
GC | 0.09 | 1.25 | 0.64–2.46 | |
AA | 0.06 | 1.14 | 0.55–2.38 | |
AC | 0.29 | 1.09 | 0.74–1.62 |
CI=confidence interval; NTD=normalised total dose; OR=odds ratio.
Adjusted for NTD, age the time of late toxicities evaluation, time since radiotherapy (months), clinic, acute skin toxicity, high blood pressure, allergy, pack-years (never, <20, ⩾20), skin type (always/moderate/seldom sunburn), clinic, marital status (single/divorced/widowed, married/partner).
A2 allele carries a duplication of 16 bp in intron 3.
P=0.06 for effect heterogeneity according to occurrence of acute skin toxicity.
Composed of haplotypes with frequencies below 5%.